Eli Lilly Agrees to Acquire Calitrix Bio for Up to $1.5 Billion
LLY Lilly(Eli) & Co
$1443.50 +1.14%
View chart & analysis → - 1Eli Lilly has agreed to acquire Calitrix Bio.
- 2The cash acquisition by Eli Lilly is valued at up to $1.5 billion.
- 3Calitrix Bio entered into this agreement to expand the development of treatments for rare blood cancers.
So what's the key point?
Eli Lilly has decided to buy Calitrix Bio for up to $1.5 billion. This allows Calitrix Bio to expand the development of treatments for rare blood cancers.
Source Reuters · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.